Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118732 | 0.91 | GRM5 (0.44) | GRM5MAP3K14 | |
| SCHEMBL5121780 | 0.87 | GRM5 (0.41) | GRM5MAP3K14 | |
| SCHEMBL5119696 | 0.85 | ALDH1A1 (0.50) | GRM5 | |
| SCHEMBL5114539 | 0.84 | ADRB1 (0.46) | GRM5 | |
| SCHEMBL5128572 | 0.82 | GRM5 (0.49) | GRM5GRIN2BMAP3K14 | |
| SCHEMBL5129125 | 0.82 | GRM5 (0.43) | GRM5MAP3K14 | |
| SCHEMBL5129376 | 0.81 | GRM5 (0.46) | GRM5MAP3K14 | |
| SCHEMBL5114711 | 0.81 | GRM5 (0.46) | GRM5MAP3K14 | |
| SCHEMBL5129681 | 0.80 | GRM5 (0.46) | GRM5MAP3K14 | |
| SCHEMBL5128492 | 0.80 | GRM5 (0.43) | GRM5MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1856107-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | Novartis AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089700-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885GRIN2D 24/4885GRIN3B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.